Page 358 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
Kitasato Univ. Biopsy-confirmed “a DRE,” generally seen every 3-6 mo “as clinical circumstances NR Increase in T category,
Hospital, Japan 154 clinically dictated.” ≥25% increase in
[11851612] localized Bone scintigraphy annually. prostate size on
prostate cancer DRE, TRUS-
1991-2000 measured volume
increase >50%,
positive finding on a
bone scan, a blastic
lesion seen on
skeletal radiograph
or soft-tissue
metastasis by
biopsy.
Not biochemical
progression (though
PSA DT calculated).

C-97